QUEEN MARY UNIVERSITY OF LONDON

Researchers at Queen Mary University of London have developed an innovative model that accurately replicates how glioblastoma tumours recur and evolve after treatment, potentially enabling personalized medicine approaches for the 3,200 UK patients diagnosed annually.

A new study published in PLOS Medicine demonstrates that self-administered HPV tests accurately identify women with cervical cancer or precancerous cells, with 40% of high-risk group participants requiring treatment.

The D-Lay MS randomized clinical trial demonstrates that high-dose vitamin D supplementation significantly reduces disease activity in patients with early multiple sclerosis, extending time to relapse or new brain lesions by over 200 days.

British genetics experts emphasize the critical need for a centralized genomic database to connect rare disease patients with clinical trials, particularly benefiting conditions affecting as few as 20 people nationwide.

• UK researchers have developed Triple T (Targeted Thermal Therapy), a groundbreaking 20-minute minimally invasive procedure that treats primary aldosteronism without removing the adrenal gland. • The FABULAS trial demonstrated Triple T's safety and effectiveness in 28 patients, with most achieving normal hormone levels after six months and many discontinuing blood pressure medications. • This innovative treatment could potentially help millions worldwide, as primary aldosteronism affects 1 in 20 people with high blood pressure but is currently underdiagnosed and undertreated.

Queen Mary University of London researchers have enrolled the first patients in a groundbreaking trial studying gene activation patterns in glioblastoma, aiming to develop personalized treatment approaches for this deadly brain cancer.

• New guidelines propose self-collected HPV tests for cervical cancer screening, potentially increasing early detection and access to care. • A new study suggests HPV self-test results can stratify women into risk groups, optimizing follow-up and colposcopy referrals. • Risk stratification using HPV variants and viral load could streamline screening in resource-limited settings, improving efficiency. • Forecasts predict a rise in diagnosed cervical cancer cases due to increased screening, emphasizing the need for thorough data analysis.

The KEYNOTE-522 trial's long-term data reveal a significant overall survival (OS) benefit with pembrolizumab plus chemotherapy in high-risk, early-stage triple-negative breast cancer (TNBC).

A Phase I trial of Ad-TD-nsIL12, an oncolytic virus, demonstrated safety and efficacy in recurrent glioblastoma patients.

Pembrolizumab combined with chemotherapy reduces recurrence risk and improves survival in high-risk, early-stage triple-negative breast cancer (TNBC).